# A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder

> **NCT02476058** · PHASE1 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 48 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** JNJ-42847922
- **DRUG:** Diphenhydramine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02476058
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-11
- **Primary completion:** 2016-01-04
- **Final completion:** 2016-01-04
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02476058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02476058, "A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02476058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*